Skip to content

Telix Pharmaceuticals Limited

TLPPF TLX

CIK 0002007191

← back to feed
Revenue (TTM)
803.79M
+55.6% YoY FY Dec 2025
Net Income (TTM)
−7.13M
−121.2% YoY FY Dec 2025
EPS Diluted (TTM)
−0.02
−121.6% YoY FY Dec 2025
Gross Margin
53.1%
FY Dec 2025
Operating Margin
3.7%
FY Dec 2025
Net Margin
-0.9%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
141.87M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
338.78M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings